Introduction
Diabetic neuropathy is a common microvascular complication of diabetes over time and one of the major cause of nontraumatic amputations. A widely-accepted deÞ nition of diabetic peripheral neuropathy is "the presence of symptoms and / or signs of peripheral nerve dysfunction in people with diabetes aft er exclusion of other causes". [1, 2] Depending on criteria, DPN is estimated to occur in 50-90% of individuals with diabetes for more than 10 years. [3] The impairment of peripheral nerve function in diabetic individuals should be regarded not as a neurological complication but as a neurological manifestation of the disease. [4, 5] It approaches 50% in most diabetic population, mainly with painful symptoms. [1] It may present as symmetric polyneuropathies, focal and multifocal neuropathies and mixed form of neuropathy. Distal symmetric sensorimotor polyneuropathy is the most common type of diabetic neuropathy and is characterized by the progressive loss of sensation and less frequently, motor function in a distal to proximal gradient. [6] Treating neuropathy is a diffi cult task for the physician and most of the conventional pain medications primarily mask symptoms. [7, 8] and have signiÞ cant side eff ects and addiction proÞ les. In the realm of physical medicine acupuncture, magnetic therapy, yoga have been found to provide beneÞ t. One of the approaches which is currently of clinical interest includes lowfrequency pulsed magnetic Þ elds, which have analgesic, neurostimulatory, trophic, and vasoactive actions. [9] This article introduces and discusses the effi cacy of low-frequency pulsed electromagnetic field which induces quasirectangular currents that can depolarize, repolarize, hyperpolarize neurons and can potentially modulate neuropathic pain and nerve impulse. It stimulates the cell power stations and enhances cell metabolism [10] resulting in higher mucosal content of RNA, DNA and improve the microcirculation due to an increased release of calcitonin gene related peptide-CGRP, [11, 12] a bioactive messenger responsible for the formation of capillaries in wound area.
The aim of the present research was to study the eff ects of diff erent frequencies (600 Hz, 800 Hz) of PEMF on motor nerve conduction parameters and pain control.
Materials and Methods
This study was carried out in Guru Nanak Dev University and Government Medical college, Amritsar, India. The study was based on randomized purposive sampling technique in which all the aspects of age, sex, duration of diabetes, were matched except the treatment patt ern in diff erent groups. Thirty subjects (mean age 52 years) with type 2 diabetes (mean duration 12 years.) in stages N 1a , N 1b , N 2a of diabetic neuropathy as deÞ ned by Dyck and Thomas classiÞ cation [13] were recruited for the present study. The batt ery of quantitative tests, which were included to conÞ rm the diabetic neuropathy, was symptom questionnaire, clinical examination, quantitative sensory testing, nerve conduction study, and autonomic nervous system testing. Confirmed cases of diabetic neuropathy examined by the senior author (B.S. Bal) were taken as subject, based upon physical and neurological examination. Clinical records of each patients were reviewed, following which, nerve conduction studies was performed. Subjects with NCV 33-48 m/sec. with average 12-year-old diabetic history were recruited for the present study. Normal value of NCV in our lab sett ing in asymptomatic healthy volunteers in the same age group was reported to be 47-54 m/sec. Subjects included were having blood glucose under steady control for a period of three months prior to the study and were found to be refractory to various pain medications available for DPN. Subjects with only distal symmetric polyneuropathy were included. Subjects with peripheral vascular disease, history of major amputation, implantable medical devices, and other systemic disease that could potentially explain their symptoms were excluded. No new analgesic drug was allowed during the study, but individuals could remain on their current regimen of antidiabetic medication. The Institutional Medical Ethics Committ ee reviewed and approved the experimental protocol. The informed consent was obtained from all the subjects prior to study. 30 individuals were taken and randomly assigned to any one of the group 1, 2, 3 with 10 subjects in each group. The experimental groups 1, 2 were treated with low-frequency pulsed electromagnetic Þ eld of 600 and 800 Hz, respectively. The actions of PEMF were directed bilaterally on calf muscles of both lower limbs; each Þ eld was applied for 30 min. duration for 12 consecutive days. Group 3 served as control and received usual medical treatment of DPN. The effi cacy of PEMF was assessed by VAS score and motor nerve conduction parameters. The baseline reading of pain on 11 point numeric pain rating scale (VAS; scale range: 0, no pain; 10, worse possible pain) and motor nerve conduction study (distal latency, nerve conduction velocity, amplitude) was done before and aft er treatment.
Statistical analysis
Analysis was conducted with SPSS soft ware. The results are expressed as mean± standard deviation. Related t-test and unrelated t-test were used for the intragroup and intergroup comparisons, respectively, to assess the statistical signiÞ cance. A 'P' value of < 0.05 was considered to be signiÞ cant.
Results
The VAS score and nerve conduction study was repeated after treatment in experimental groups. The same readings were taken aft er 12 days for control group without any intervention. The VAS score decreased by 66.6, 63.25, and 22.5% in groups 1, 2, 3 respectively. There was a greater decrease in mean values for group 1 [ Figure 1 ].
The distal latency value in right peroneal nerve was 6.13 ± 3.18 and 3.88 ± 0.97 before and aft er treatment of group 1, respectively (t = 2.18) [ Figure 2 ]. The mean values for NCV in right peroneal nerve were 36.23 ± 2.09 and 39.44 ± 2.83 before and aft er treatment, respectively (t = 2.89) [ Figure 3 ]. In group 1, distal latency in left peroneal nerve was found to be 4.71 ± 0.99 and 3.44 ± 0.98 before and aft er treatment, respectively (t = 2.88) [ Figure 2 ]. The mean values of NCV in left peroneal nerve were 36.27 ± 2.68, 38.92 ± 2.91 pre and post-treatment, respectively (t = 2.12) [ Figure 3 ].
On left leg of group 2, the results for distal latency were 4.47± 0.96 and 4.28 ± 0.94 (t = 0.43) before and aft er treatment, respectively [ Figure 2 ]. The mean values of NCV were 37.58 ± 6.15, 40.98 ± 6.63 (t= 2.56) in pre and post treatment conditions, respectively. On right leg of group 2, the results for distal latency, NCV were 5.59 ± 0.96, 4.55 ± 0.78 (t =2.6); 38.80 6.33, 41.38 ± 5.44 (t = 2.11) for pre and post-treatment condition, respectively [ Figure 4 ]. The amplitude were found to be nonsigniÞ cant statistically in both the experimental groups [ Figure 4 ]. In group 3, the distal latency in right peroneal nerve showed 4.45 ± 1.58, 4.77 ± 1.77 value before and aft er 12 days, respectively [ Figure 2 ]. The NCV values for right peroneal nerve was 38.39 ± 6.41, 37.86 ± 6.47 before and aft er 12 days, respectively [ Figure 3 ]. The left peroneal nerve showed distal latency 4.70 ± 1.11, 4.80 ± 1.34 before and aft er 12 days respectively [ Figure 2 ]. The mean values of NCV were 39.35 ± 6.37, 37.99 ± 6.55 before and aft er 12 days [ Figure 3 ]. The distal latency, NCV, amplitude were non signiÞ cant (P<0.05) in control group.
Discussion
In the present study, pulsed electromagnetic field therapy (600 and 800 Hz) was explored to study its eff ect on the state of segmental peripheral neuromotor apparatus and neuropathic pain experienced by patients. The primary aim of the study was to evaluate the eff ect of diff erent frequencies of PEMF in diabetic polyneuropathy. In DPN, the pain may result due to various reasons such as increase in diff erent signals from degenerating nociceptive aff erent Þ bers, depolarization because of dysregulation of normal sodium, [14] calcium [15] and potassium [16] channel activities. It is well known that a biological system exposed to a physical stimulus (PEMF) is able to detect its presence and to modify its own biological activity depending on the characteristic of the applied stimulus such as mechanic, electric, or magnetic. In particular, static and time varying magnetic Þ elds have been shown to alter animal and human behaviors such as pain perception. [17] The pain relief in experimental groups 1 and 2 could be att ributed to the eff ect that magnetic Þ elds aff ects pain perception by direct eff ects in form of neuron Þ ring, calcium ion movement, endorphin levels, acupuncture action, and nerve regeneration. [18] [19] [20] A gating response with simultaneous stimulation of the Aδ Þ bers producing an inhibitory antinociceptive eff ect on C Þ bers which is compatible with Melzak-Wall Hypothesis. [21] The pain is most likely to arise from increased activity of injured small -diameter regenerating Þ bers, [15] which Þ re rapidly and at abnormally low thresholds. [22] The PEMF inß uence diabetic neurons and cell membrane of cutaneous nociceptors thereby inducing change in the cellular [23] and pericellular microenvironment. [24, 25] The possible reason of pain reduction in group 3 is persistent controlled glycemic control. The strict glycemic control is a best measure to halt deterioration of DPN. [26] The motor nerve conduction parameters (latency and NCV) showed signiÞ cant improvement in group 1, 2 with bett er mean values in group 1. As demonstrated by Fagerberg's, [27, 28] DPN is a result of diabetic angiopathy and found the correlation between neuropathic symptoms and duration of diabetes and histological abnormalities of the vasa nervorum. [29] The decrease in motor nerve conduction velocity (MCV) can be explained as a result of abnormality in the vasa nervorum. The experimental groups showed improvement in distal latency, NCV aft er treatment which can be att ributed to indirect eff ect of PEMF, that is it augments angiogenesis by stimulating endothelial release of Þ broblast growth factor beta -2 (FGF -2). [30] Smith [31] found that PEMF stimulate the arteriolar microvessel diameters in rat cremester muscle, which further support that it improves the microenvironment for the tissues leading to regeneration. [32, 33] Other probable reason for the improvement may be that it stimulates neurotrophic factors that is known to play an important role in the development, maintenance, and survival of neuronal tissues. [3] Few studies suggested that endoneurial capillaries in peripheral nerves of the diabetes are thickened [29] and perineurial basement membrane are widened. [34] A permeability disorder at the blood nerve or blood perineurial barrier in diabetics could lead to endoneurial metabolic derangements, however possibly resulting in neuropathy. PEMF by targeting at increased circulation and anti inß ammatory eff ects combined with the pain relief and restoration of normal nerve conduction lead to reversal of the damage that cause the peripheral neuropathy. Recently, it has been observed that PEMF modulates the neurite growth in vitro and nerve regeneration in vivo, which further explains the improvement obtained in results of group 1 and 2. None of the group showed signiÞ cant changes in amplitude reading obtained in pre and post-treatment reading. The probable reason could be that amplitude of compound muscle action potential correlate with the number of nerve Þ bers recruited. As DPN is best classiÞ ed as axonal neuropathy, in that predominant neuropathic feature is nerve Þ ber loss. [35] The eff ects of PEMF is to trigger a biologic response such as cell proliferation that represent the basic eff ect to explain some relevant results. It enhances nerve regeneration and accelerates recovery in experimentally divided and sutured peroneal nerve which can improve number of nerve Þ ber and thereby amplitude achieved in nerve conduction study. No diff erence in pre and post reading of amplitude could be att ributed to short duration of treatment, which was inadequate to get the positive changes in amplitude. Comparative analysis showed non-signiÞ cant diff erences in group 1, 2 aft er treatment. The mean diff erence was found to be more in group 1 (600 Hz) in both legs except NCV mean value which was higher in left leg of group 2 (800 Hz). The probable reason for this could be small sample size, short duration of study and individual variations.
In summary, it can be concluded that available data provide the evidence that PEMF treatment has the potential to modulate neuropathic pain and nerve impulse. It may be due to decrease in endoneural hypoxia, perineural edema, ischemia of peripheral nerves, and improved microcirculation that leads to positive changes aft er treatment sessions. The limitations of the study were small sample size, short term study, exclusion of patients other then distal symmetric polyneuropathy, and lack of follow-up.
Conclusions
The present study provides convincing data regarding the effect of PEMF on neuropathic pain and nerve impulse. Considering its benefit and safety, lowfrequency PEMF can be used as an adjunct in the management of diabetic neuropathy cases. Limitations of this study include small sample size, short duration of treatment, and nonavailability of follow-up data.
